申请人:CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
公开号:US10376476B2
公开(公告)日:2019-08-13
The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to the use of a panicein or a derivative thereof, to decrease or inhibit, in vitro or ex vivo, the Patched receptor drug efflux activity, in particular the chemotherapeutic drug efflux activity and chemotherapy resistance.
The present disclosure further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The compound of the invention can indeed be advantageously used, in combination with at least one chemotherapeutic drug, for treating cancer, for preventing cancer metastasis and/or for preventing cancer recurrence in a subject.
The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject, as well as kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.
本发明涉及医药和癌症治疗领域。本发明更具体地涉及一种帕尼辛或其衍生物在体外或体内降低或抑制帕特受体药物外流活性,特别是化疗药物外流活性和化疗耐药性的用途。
本公开进一步涉及此类化合物的用途,特别是制备药物组合物,以允许或提高有需要的受试者治疗癌症的效率。本发明的化合物确实可以与至少一种化疗药物联合使用,有利地用于治疗癌症、防止癌症转移和/或防止受试者癌症复发。
本发明还公开了用于预防或治疗癌症、癌症转移和/或癌症复发的方法,以及适用于制备根据本发明的组合物和/或实施本文所述方法的试剂盒。